{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:23:37Z","timestamp":1758126217756},"reference-count":45,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two multicenter, randomized, placebo\u2010controlled, adaptive\u2010design trials of desvenlafaxine for fibromyalgia syndrome (FMS) were conducted. In study 1, male and female patients were randomized to a 27\u2010week treatment with placebo or desvenlafaxine 50, 100, 200, or 400 mg\/d. In study 2, female patients were randomized to an 8\u2010week treatment with placebo, desvenlafaxine 200 mg\/d, or pregabalin 450 mg\/d after a placebo run\u2010in. The primary efficacy end point was change from baseline in numeric rating scale (NRS) pain score. Protocol\u2010specified interim analyses were planned after 12 (study 1) and 8 (study 2) weeks of treatment. Safety data were collected. In all, 697 patients were randomly assigned to treatment in study 1. At the interim analysis (n = 346), none of the desvenlafaxine doses met the efficacy criteria (mean [SE] advantage over placebo, \u20130.21 [0.36] to 0.04 [0.35]), and the study was terminated. Study 2 was stopped for business reasons before the planned interim analysis. NRS scores in week 8 were \u20131.98 (0.37), \u20131.60 (0.37), and \u20131.70 (0.38) for placebo (n = 26), desvenlafaxine 250 mg\/d (n = 24), and pregabalin 450 mg\/d (n = 21), respectively; neither active treatment differed significantly from placebo. Desvenlafaxine was generally safe and well tolerated. Efficacy of desvenlafaxine for pain associated with FMS was not demonstrated.<\/jats:p>","DOI":"10.1002\/cpdd.271","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T15:36:29Z","timestamp":1462289789000},"page":"224-233","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Experience With Desvenlafaxine in Treatment of Patients With Fibromyalgia Syndrome"],"prefix":"10.1002","volume":"6","author":[{"given":"Rob","family":"Allen","sequence":"first","affiliation":[{"name":"Formerly of Pfizer Inc  Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Sharma","sequence":"additional","affiliation":[{"name":"MMS Holdings Inc  Canton MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suna","family":"Barlas","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000221817.46231.18"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20140"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-8-27"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/959036"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2009.03.012"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181cf599f"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.02.018"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2000.06279.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.09.008"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D112"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(98)71375-1"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P218"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.06.031"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100365"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.103382"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900020125"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2005.08.018"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20983"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20485"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000058749.49264.BD"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.05.010"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181cb406e"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.02.024"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.11.009"},{"issue":"2","key":"e_1_2_9_26_1","first-page":"398","article-title":"The efficacy and safety of milnacipran for treatment of fibromyalgia","volume":"36","author":"Mease PJ","year":"2009","journal-title":"a randomized, double\u2013blind, placebo\u2013controlled trial. J Rheumatol."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27559"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090884"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2012.03.003"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08r04516blu"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.08.009"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3281e2c84b"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1105"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0504"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.01.050"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.65.12_suppl_4.S32"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.10.026"},{"issue":"23","key":"e_1_2_9_38_1","first-page":"13","article-title":"Product discovery and development: shaking the cup for pain","volume":"19","author":"Usdin S.","year":"2011","journal-title":"BioCentury"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511666971.011"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.06.019"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000275528.01263.6c"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-013-0011-1"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2011.05.008"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.153"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.01.029"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01480.x"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.271","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.271","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:59:07Z","timestamp":1694998747000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1002\/cpdd.271"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.271","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,17]]}}}